Why is folinic acid given with 5 fu

You will usually be given folinic acid in the chemotherapy day unit or during a stay in hospital. A chemotherapy nurse will give it to you at the same time as your chemotherapy treatment. During treatment you will usually see a cancer doctor, a chemotherapy nurse, or a specialist nurse, and a specialist pharmacist.

This is who we mean when we mention doctor, nurse or pharmacist in this information. Before or on the day of treatment, a nurse or person trained to take blood phlebotomist will take a blood sample from you. This is to check that your blood cells are at a safe level to have the chemotherapy part of the treatment.

You will see a doctor or nurse before you have treatment. They will ask you how you have been feeling. If your blood results are okay, the pharmacist will prepare your drugs.

Your nurse will tell you when your treatment is likely to be ready. Your nurse will give you the folinic acid as a drip infusion or injection through one of the following:. You may also have folinic acid as a tablet. Before you leave hospital, the nurse or pharmacist will give you the tablets to take at home. It is important to take your tablets exactly as explained. This is to make sure they work as well as possible for you.

Your nurse will give you telephone numbers for the hospital. If you feel unwell or need advice, you can call them at any time of the day or night. Save these numbers in your phone or keep them somewhere safe. We cannot list every side effect for this treatment. There are some rare side effects that are not listed. Clin Cancer Res 4 : — Anti-Cancer Drugs 11 : — Grem J 5 fluorouracil: forty-plus and still ticking.

A review of its preclinical and clinical development. Invest New Drugs 18 : — Clin Cancer Res 7 : — Hoff PM, Pazdur R Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents. Sem Oncol 26 : 52— Drugs 59 Suppl 4 : 29— Keyomarsi K, Moran RG Mechanism of the cytotoxic synergism of fluorouropyrimidines and folinic acid in mouse leukemic cells.

J Biol Chem 28 : — Google Scholar. Kones R Folic acid. An update with new recommended daily allowances. South Med J 83 : — Eur J Cancer 26S abstract Anticancer Res 20 : — Moran RG, Scanlon KL Schedule-dependent enhancement of the cytotoxicity of fluoropyridimes to human carcinoma cells in the presence of folinic acid. Cancer Res 51 : — Clin Cancer Res 5 : — Proc Am Soc Clin Oncol 17 : Pizzorno G, Sun Z, Handschumacher RE Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil.

Biochem Pharmacol 49 : — Proc of AACR abstract Anti-Cancer Drugs 8 : — Adv Exp Med Biol : 97— Hepatogastroenterology 46 : — Methods Cell Biol 33 : — Adv Enzyme Regul 26 : 17— Download references. You can also search for this author in PubMed Google Scholar.

Correspondence to G Milano. From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.

Reprints and Permissions. Fischel, J. Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity. Br J Cancer 86, — Download citation. Received : 19 July Revised : 23 October Accepted : 10 January Published : 02 April Issue Date : 08 April Anyone you share the following link with will be able to read this content:.

Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Journal of Gastrointestinal Cancer BMC Cancer British Journal of Cancer BMC Cell Biology Clinical and Translational Oncology Advanced search.

Skip to main content Thank you for visiting nature. Download PDF. This article has been updated. Abstract The combination of 5-fluorouracil-folinic acid and oxaliplatin has led to a significant improvement of chemotherapy efficacy in advanced pretreated colorectal cancer.

Main Colorectal cancer remains a leading cause of cancer deaths in western countries and approximately half of all patients develop metastatic disease carrying a poor prognosis. Drug administration schedule The human colorectal cancer cell line, WiDr, was used in the present study. Evaluation of mitochondrial membrane permeability Cells were treated with or without various concentrations of drugs as described above.

TS measurements and reduced folate determination TS activity was measured according to the tritium-release assay described by Spears and Gustavsson Statistical analysis Comparisons between different tested conditions were done with Wilcoxon non parametric paired tests for experiments described in Figures 1 , 2A,B and 3. Figure 1. Full size image. Figure 2. Figure 3. Table 1 Time course of the impact of drugs on cell cycle Full size table. Figure 4. Figure 5.

Discussion The objective of the present study was, when considering the Oxa-FUFA combination, to examine the impact of one given drug on the cellular determinants of cytotoxic activity of the other drug. Change history 16 November This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication. J Clin Oncol 14 : — Article Google Scholar. J Clin Oncol 18 : — Lancet : — J Clin Oncol 20 : — Proc Am Assoc Cancer Res 40 : abstract Freedman LS Tables of the number of patients required in clinical trials using the logrank test.

Stat Med 1 : — J Clin Oncol 22 : 23— Grothey AA, Sargent D, Goldberg R, Schmoll HJ Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 : — Cancer Res 49 : — J Am Stat Assoc 53 : — Ann of Oncol 13 : — J Clin Oncl 16 : — Biometrics 35 : — CA Cancer J Clin 55 : 74— Pocock SJ, Simon R Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials.

Biometrics 31 : — J Clin Oncol 7 : — Ann Oncol 9 : — Biochem Pharmacol 52 : — N Engl J Med : — J Clin Oncol 23 : — Oncology 69 : — J Natl Cancer Inst 86 : — J Natl Cancer Inst 92 : — J Clin Oncol 16 : — Download references.

You can also search for this author in PubMed Google Scholar. Correspondence to J Souglakos. From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3. Reprints and Permissions. Souglakos, J. Br J Cancer 94, — Download citation. Received : 05 October Revised : 19 January Accepted : 23 January Published : 28 February Issue Date : 27 March Anyone you share the following link with will be able to read this content:.

Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. BMC Cancer World Journal of Surgical Oncology British Journal of Cancer Signal Transduction and Targeted Therapy Journal of Gastrointestinal Surgery Advanced search. Skip to main content Thank you for visiting nature.